Business Context and Reporting Period
This Form 8-K, dated July 12, 2019, reports on a special meeting of stockholders held by Flex Pharma, Inc. (the "Registrant"). The filing details the approval of a merger with Salarius Pharmaceuticals, LLC ("Salarius"), a reverse stock split, and a corporate name change. The Registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and transaction approval; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
On July 12, 2019, Flex Pharma stockholders approved all proposals necessary to consummate the merger with Salarius. As of the record date, 18,069,476 shares were outstanding, with 13,893,145 shares (76.89%) present or represented by proxy, constituting a quorum.
- Proposal 1 (Merger Approval): Approved. 9,143,713 votes For; 331,064 Against; 33,097 Abstain. This proposal authorized the issuance of Flex Pharma common stock to Salarius members and the resulting change of control.
- Proposal 2 (Reverse Stock Split): Approved. 11,468,578 votes For; 1,872,404 Against; 80,277 Abstain. This amends the Certificate of Incorporation to effect a reverse stock split.
- Proposal 3 (Name Change): Approved. 9,110,216 votes For; 360,741 Against; 36,917 Abstain. The company will change its name to "Salarius Pharmaceuticals, Inc."
- Proposal 4 (Adjournment): Approved. 11,894,647 votes For; 1,114,883 Against; 411,729 Abstain.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. It references the definitive proxy statement/prospectus/information statement (filed April 29, 2019, with a supplement on June 27, 2019) for detailed information regarding the transaction, risks, and contingencies. The document includes a non-solicitation notice stating it is not an offer to sell securities.
Investor Verification Checklist
- Verify the final terms of the merger agreement and the exchange ratio for Salarius members in the Form S-4 (File No. 333-229666).
- Confirm the specific ratio of the reverse stock split approved in Proposal 2, as the exact ratio is not detailed in this 8-K.
- Review the definitive proxy statement for details on the issuance of warrants and rights to Flex Pharma stockholders.
- Monitor the effective date of the name change to "Salarius Pharmaceuticals, Inc." and the subsequent trading symbol change on the Nasdaq Capital Market.